Sifalimumab

Sifalimumab
	Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α
Clinical data
ATC code	none;
Identifiers
CAS Number	1006877-41-3 ;
ChemSpider	none;
UNII	XOY1YA7RMC;
KEGG	D09668;
Chemical and physical data
Formula	C6518H10008N1724O2032S38
Molar mass	146252.08 g·mol−1
	(what is this?) (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.^[1]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.^[2]^[3]^[4]

References

↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
↑ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
↑ "Sifalimumab". AdisInsight. Retrieved 31 July 2017.
↑ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.

[2] "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.

[3] "Sifalimumab". AdisInsight. Retrieved 31 July 2017.

[4] "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.

[1]

[2]

[3]

[4]